BRAINSTORM CELL THERAPEUTICS INC. (BCLI) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 3.48M USD | Research and Development Expense |
| Revenue | (m) | |
| Stock-based compensation | 3.18M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -9.95M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.48M | (m) | $3.18M | $-9.95M | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $3.63M | (m) | (m) | $-8.91M | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $4.17M | (m) | $1.52M | $-9.95M | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $5.05M | (m) | $1.58M | $-10.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $5.19M | (m) | $1.61M | $-11.90M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $4.99M | (m) | $1.30M | $-12.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $4.65M | (m) | $750.00K | $-11.69M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $4.63M | (m) | $492.00K | $-13.31M | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $6.91M | (m) | $862.00K | $-16.30M | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $8.78M | (m) | $1.66M | $-18.76M | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $10.75M | (m) | $1.49M | $-21.44M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $11.50M | (m) | $1.92M | $-21.55M | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $11.95M | (m) | $1.76M | $-22.36M | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $14.26M | (m) | $1.18M | $-24.50M | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $13.96M | (m) | $1.68M | $-24.82M | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $15.18M | (m) | $1.95M | $-26.12M | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $15.02M | (m) | $1.75M | $-24.55M | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $13.51M | (m) | $1.58M | $-23.09M | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $15.23M | (m) | $1.37M | $-24.54M | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $4.00M | (m) | $1.09M | $-29.82M | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $2.25M | (m) | $1.91M | $-29.03M | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $4.34M | (m) | $2.46M | $-30.30M | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $22.33M | (m) | $2.56M | $-31.68M | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $19.70M | (m) | $2.38M | $-27.86M | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $21.84M | (m) | $1.58M | $-28.92M | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $19.70M | (m) | $842.00K | $-26.38M | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $17.20M | (m) | $789.00K | $-23.00M | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $14.88M | (m) | $1.03M | $-20.77M | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $12.85M | (m) | $1.05M | $-18.45M | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $10.77M | (m) | $1.13M | $-16.68M | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $8.29M | (m) | $1.02M | $-14.06M | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $2.87M | (m) | $798.00K | $-8.39M | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $2.06M | (m) | $796.00K | $-7.55M | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $1.01M | (m) | $717.00K | $-5.54M | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $977.00K | (m) | $616.00K | $-5.00M | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $2.87M | (m) | $505.00K | $-5.89M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $2.49M | (m) | $443.00K | $-5.13M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $2.21M | (m) | $648.00K | $-5.04M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $2.25M | (m) | $756.00K | $-5.08M | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $2.75M | (m) | $655.00K | $-5.83M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $3.47M | (m) | $771.00K | $-6.76M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $4.69M | (m) | $830.00K | $-8.14M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $4.95M | (m) | $943.00K | $-8.54M | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $5.77M | (m) | $1.41M | $-11.63M | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $5.83M | (m) | $1.48M | $-11.49M | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $5.34M | (m) | $1.34M | $-9.37M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $4.77M | (m) | $1.22M | $-9.25M | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $3.98M | (m) | $1.01M | $-7.72M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $3.21M | (m) | $594.00K | $-6.39M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $3.08M | (m) | $803.00K | $-5.90M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $2.92M | (m) | $872.00K | $-4.87M | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $2.35M | (m) | (m) | $-4.24M | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $2.28M | (m) | (m) | $-4.31M | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $1.92M | (m) | (m) | $-3.64M | $-81.00K | (m) | (m) | (m) | Reported |
| 2012-12-31 | $1.77M | (m) | (m) | $-3.42M | $-93.00K | (m) | (m) | (m) | Reported |
| 2012-09-30 | $2.14M | (m) | (m) | $3.56M | $-320.00K | (m) | (m) | (m) | Reported |
| 2012-06-30 | $1.59M | (m) | $1.00M | $3.81M | $-150.00K | (m) | (m) | (m) | Reported |
| 2012-03-31 | $1.79M | (m) | $1.28M | $4.08M | $37.00K | (m) | (m) | 110.16× | Reported |
| 2011-12-31 | $1.69M | (m) | $1.14M | $3.91M | $-151.00K | (m) | (m) | (m) | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $1.04M | (m) | $388.00K | $2.40M | $189.00K | (m) | (m) | 12.70× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| Pluri Inc. (PLUR) | $0.014B | ||
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |